BOULDER – November 02, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) granted inducement stock options on 17,250 shares and restricted stock units covering 8,626 shares to two new non-executive employees on October 30, 2026.

Options carry a $38.90 exercise price set at the grant-date close

Each option has an exercise price of $38.90 per share, equal to Edgewise's closing share price on the grant date. The awards were made under the company's 2024 Inducement Equity Incentive Plan.

Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.